Roche’s SKYSCRAPER-01 Study: Update on Tiragolumab’s Role in Advanced Lung Cancer Therapy

Roche’s SKYSCRAPER-01 Study: Update on Tiragolumab’s Role in Advanced Lung Cancer Therapy

(IN BRIEF) Roche provided an update on its Phase III SKYSCRAPER-01 study, evaluating tiragolumab in combination with Tecentriq® for patients with PD-L1-high, advanced, or metastatic non-small cell lung cancer (NSCLC). The study did not meet its primary endpoint of improving overall survival, though the safety profile remained consistent with no new concerns. Roche will continue to analyze tiragolumab in other Phase III trials across different cancer settings, with additional data expected next year. Detailed results from SKYSCRAPER-01 will be presented at a medical meeting in 2025.

(PRESS RELEASE) BASEL, 27-Nov-2024 — /EuropaWire/ — Roche has released an update on the Phase III SKYSCRAPER-01 study, which assessed the efficacy of tiragolumab combined with Tecentriq® (atezolizumab) versus Tecentriq alone in patients with PD-L1-high, locally advanced, or metastatic non-small cell lung cancer (NSCLC). The study involved 534 participants who were randomized to receive either the tiragolumab-Tecentriq combination or a placebo with Tecentriq.

Study Findings

The trial did not meet its primary endpoint of improving overall survival at the final analysis. However, the safety profile remained consistent with earlier findings, and no new safety concerns were identified. Roche plans to present a detailed analysis of the data at a medical meeting in 2025.

Future Directions

Roche emphasized its ongoing commitment to reviewing its research programmes and adapting based on emerging findings. Additional data from other Phase III studies evaluating tiragolumab across various settings and tumour types are expected next year.

About tiragolumab
Tiragolumab is an investigational immune checkpoint inhibitor with an intact Fc region. Tiragolumab selectively binds to TIGIT, a novel inhibitory immune checkpoint which suppresses the immune response to cancer.

About Tecentriq
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Media Contacts:

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Roche Investor Relations

Investor Relations North America

SOURCE: Roche